Responses
Clinical/translational cancer immunotherapy
Original research
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
Compose a Response to This Article
Other responses
No responses have been published for this article.